Additionally, there are also conflicting reports in lung cancer, with findings pinpointing that USP10 enhanced the stability and activity of PTEN to inhibit non-small cell lung cancer cell proliferation [39], whereas another research suggesting that USP10 deubiquitinated oncogenic protein HDAC6 to confer cisplatin resistance of non-small cell lung cancer [40]. Here, USP10 is linked to non-small cell lung carcinoma.